Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares traded down 5.3% on Thursday . The company traded as low as $10.50 and last traded at $11.12, with a volume of 412,981 shares changing hands. The stock had previously closed at $11.74.

A number of research analysts have weighed in on the company. Goldman Sachs Group Inc. assumed coverage on Momenta Pharmaceuticals in a report on Monday, June 6th. They issued a “neutral” rating and a $14.00 target price on the stock. Brean Capital reissued a “buy” rating and issued a $19.00 target price on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Zacks Investment Research raised Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, Leerink Swann reissued an “outperform” rating and issued a $18.00 target price (down previously from $21.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $18.40.

The stock has a 50 day moving average of $11.12 and a 200-day moving average of $10.45. The firm’s market capitalization is $762.82 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.01. The firm had revenue of $26.40 million for the quarter, compared to analysts’ expectations of $23.55 million. During the same quarter in the previous year, the firm posted ($0.04) EPS. The firm’s revenue for the quarter was down 41.2% compared to the same quarter last year. On average, equities analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.40) EPS for the current fiscal year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the business’s stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $10.18, for a total transaction of $59,858.40. Following the sale, the president now owns 349,521 shares in the company, valued at approximately $3,558,123.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Other hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Momenta Pharmaceuticals by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 423,158 shares of the biotechnology company’s stock valued at $6,279,000 after buying an additional 18,504 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Momenta Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 113,170 shares of the biotechnology company’s stock valued at $1,679,000 after buying an additional 1,801 shares during the period. GSA Capital Partners LLP boosted its position in shares of Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock valued at $1,310,000 after buying an additional 66,130 shares during the period. California Public Employees Retirement System boosted its position in shares of Momenta Pharmaceuticals by 2.9% in the fourth quarter. California Public Employees Retirement System now owns 200,600 shares of the biotechnology company’s stock valued at $2,977,000 after buying an additional 5,600 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Momenta Pharmaceuticals by 9.9% in the fourth quarter. Rhumbline Advisers now owns 75,638 shares of the biotechnology company’s stock valued at $1,122,000 after buying an additional 6,835 shares during the period.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.